GlassScriptPhysician profile
William D Mcclendon
NPI 1790735652
$10,030.12
in general payments reported to CMS, 2019-2025
42 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $696 · 2021: $1,234 · 2022: $1,364 · 2023: $1,976 · 2024: $2,155 · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,950 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,950.48 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,488.20 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astellas Pharma US INC | $935.39 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $831.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $820.04 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $625.98 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $489.95 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $447.17 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.70 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $428.55 | 2023-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $358.88 | 2023-2025 | Rexulti, Jynarque |
| Pfizer INC. | $349.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $335.67 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Amgen INC. | $299.49 | 2023-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $229.18 | 2022-2025 | |
| Glaxosmithkline, LLC. | $224.87 | 2023-2025 | Arexvy, Shingrix, Boostrix |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcclendon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.